Last reviewed · How we verify

NCT03487302

White Matter Hyperintensities Burden in Adult Patients With Cyanotic Congenital Heart Disease: a Pilot Study

Completed Last updated 13 September 2022
What this trial tests

trial testing Brain MRI in Aging, Premature in 146 participants. Completed in 31 December 2021.

Timeline
17 October 2017
Primary endpoint
31 December 2021
31 December 2021

Quick facts

Lead sponsorIRCCS Policlinico S. Donato
StatusCompleted
Study typeOBSERVATIONAL
Enrollment146
Start date17 October 2017
Primary completion31 December 2021
Estimated completion31 December 2021
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS Policlinico S. Donato

Who can join

20 and older, any sex, with Aging, Premature or Congenital Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims at investigating the role of cyanotic congenital heart disease (cCHD) on brain aging. The investigators assume that due to congenital and acquired cardiovascular abnormalities, cCHD patients could show radiologic (and clinical) signs of precocious brain aging and eventual cognitive decline.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Brain MRI

Trials testing the same drug.

Other recruiting trials for Aging, Premature

Currently open trials in the same condition.

Other IRCCS Policlinico S. Donato trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03487302.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing